Last reviewed · How we verify
Renin-angiotensin-aldosterone system inhibitors — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Renin-angiotensin-aldosterone system inhibitors (Renin-angiotensin-aldosterone system inhibitors) — National Heart Centre Singapore.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Renin-angiotensin-aldosterone system inhibitors TARGET | Renin-angiotensin-aldosterone system inhibitors | National Heart Centre Singapore | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Renin-angiotensin-aldosterone system inhibitors CI watch — RSS
- Renin-angiotensin-aldosterone system inhibitors CI watch — Atom
- Renin-angiotensin-aldosterone system inhibitors CI watch — JSON
- Renin-angiotensin-aldosterone system inhibitors alone — RSS
Cite this brief
Drug Landscape (2026). Renin-angiotensin-aldosterone system inhibitors — Competitive Intelligence Brief. https://druglandscape.com/ci/renin-angiotensin-aldosterone-system-inhibitors. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab